Queensland Renal Biopsy Registry Sub Study: Multi-centre prospective observational cohort study investigating association between anti-neutrophil cytoplasmic antibodies (ANCA) results and relapse of ANCA associated vasculitis

Not Applicable

Recruiting

• Conditions: ANCA Vasculitis; Inflammatory and Immune System - Autoimmune diseases; Renal and Urogenital - Other renal and urogenital disorders; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Respiratory - Other respiratory disorders / diseases; Skin - Other skin conditions

• Registration Number: ACTRN12622000012774
• Lead Sponsor: Dr Dwarakanathan Ranganathan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-11
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 109

Inclusion Criteria

Patients with ANCA vasculitis based on compatible serology, radiology, histology and/or biochemistry.

Participants need to have been enrolled into the Queensland Renal Biopsy Registry

Exclusion Criteria

ANCA negative vasculitis

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relapse rate in patients with two-fold ANCA rise compared to those without an ANCA rise.<br><br>Method: Audit of study records[Monitoring post induction 3 monthly for at least 3 years];Relapse rate in patients with four-fold ANCA rise compared to patients without ANCA rise<br><br>Method: Audit of study records[Monitoring post induction 3 monthly for at least 3 years];Identify if initial induction therapy (rituximab vs cyclophosphamide) impacts the performance of these assays in predicting relapse. <br><br>Method: Audit of study records[monitoring 3 monthly for at least 3 years post induction]

Secondary Outcome Measures

Name	Time	Method
il<br>[N/A]